ACM
FPRX

Aquilo Capital Management’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Aquilo Capital Management’s Portfolio FPRX Stock Details FPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-64,881
Closed -$1.02M – 15
2018
Q2 		$1.02M Buy
+64,881
New +$1.13M 0.85% 13

Other funds holding FPRX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Aquilo Capital Management's FPRX Position: Q3 2018 in Review

Aquilo Capital Management sold out of Five Prime Therapeutics, Inc. (FPRX) in Q3 2018, closing a stake of 64,881 shares — an estimated $1.02M sold.

Aquilo Capital Management first reported a position in FPRX in Q2 2018 and held it in 1 quarter. The position peaked at $1.02M in Q2 2018. 114 funds tracked by Wall St. Rank hold FPRX as of Q3 2018.

  • Aquilo Capital Management reported no remaining Five Prime Therapeutics, Inc. position as of Q3 2018 after selling out during the quarter.
  • Aquilo Capital Management sold 64,881 Five Prime Therapeutics, Inc. shares in Q3 2018, an estimated $1.02M.
  • Aquilo Capital Management first reported a position in Five Prime Therapeutics, Inc. in Q2 2018 and held it in 1 quarter.
  • Aquilo Capital Management's Five Prime Therapeutics, Inc. position peaked at $1.02M in Q2 2018.
  • 114 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q3 2018.

Based on Aquilo Capital Management's 13F filing for Q3 2018, filed 14 Nov 2018.